

**REGISTERED CHARITY NUMBER: 327206**

**Trustees' Report and  
Audited Financial Statements for the Year Ended 31 December 2022  
for  
Drug Safety Research Trust**

**Drug Safety Research Trust**

**Contents of the Financial Statements  
for the Year Ended 31 December 2022**

	<b>Page</b>
<b>Reference and Administrative Details</b>	1
<b>Trustees' Report</b>	2 to 9
<b>Statement of Trustees' Responsibilities</b>	10
<b>Report of the Independent Auditors</b>	11 to 14
<b>Statement of Financial Activities</b>	15
<b>Statement of Financial Position</b>	16
<b>Statement of Cash Flows</b>	17
<b>Notes to the Statement of Cash Flows</b>	18
<b>Notes to the Financial Statements</b>	19 to 27
<b>Detailed Statement of Financial Activities</b>	28 to 29

**Drug Safety Research Trust**

**Reference and Administrative Details  
for the Year Ended 31 December 2022**

**TRUSTEES**

Professor Kenneth Ross Paterson MB ChB FRCP FFPM FBPhS (Chairman)  
Professor John Camm QHP BSc MD FRCP FESC FACC FAHA FCGC CSJ  
Professor Martin Vessey CBE MD FRCP FRCOG FRCGP FFPH FMedSci FRS  
Professor Allan Hunter Young MB, ChB, MPhil, PhD, FRCPC, FRCPsych  
Professor Isla Mackenzie MB ChB PhD PGCertMedEd FRCP Edin FBPhS FBIHS

**DIRECTOR**

Professor Saad Shakir MB ChB LRCP&S FRCP FFPM FISPE MRCP

**PRINCIPAL ADDRESS**

Bursledon Hall  
Blundell Lane  
Southampton  
SO31 1AA

**REGISTERED CHARITY NUMBER** 327206

**INDEPENDENT AUDITORS**

Cartwrights  
Chartered Accountants and Business Advisors  
Statutory Auditor  
Regency House  
33 Wood Street  
Barnet  
Hertfordshire  
EN5 4BE

**PROFESSIONAL ADVISERS**

Solicitors  
Paris Smith LLP  
Number 1 London Road  
Southampton  
S015 2AE

Investment advisers  
Investec Wealth and Investment Limited  
30 Gresham Street  
London  
EC2V 7QN

**PRINCIPAL BANKERS**

Lloyds Bank plc  
92-94 Above Bar St  
Southampton  
SO14 7DT

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

The trustees present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### **OBJECTIVES AND ACTIVITIES**

##### **Objectives and aims**

The Trust by way of its operational unit, the DSRU, undertakes all forms of studies and evaluations of the safety of medicines for the public benefit, including methodological research to improve existing methods including:

- Studies to examine the safety of medicines, including new medicines, new formulations for existing medicines and when medicines are used for new indications or in new populations, or when safety issues or questions about the use, benefit-risk balance or effectiveness of medicines arise. Frequently such DSRU studies are part of risk management plans for medicines which are now statutory requirements in the EU.
- Studies on established medicines when safety, scientific, utilisation or regulatory issues, questions, enquiries or needs for submissions arise. The issues include risk management & minimisation and methodological questions. The studies can be part of the UK and the EU regulatory requirements for risk management of medicines, though not exclusively.
- Conducting studies to address specific safety, public health, scientific, benefit-risk balance of medicines and vaccines, utilisation and usage and regulatory issues or concerns.
- Conducting utilisation studies for medicines and vaccines to enable understanding the use and effects of products on the healthcare system and behaviours and responses of patients and healthcare professionals.
- Use of healthcare databases to conduct drug safety studies.
- Establishing registries to conduct safety and utilisation studies.
- Working with doctors to undertake studies to examine specific safety questions and medical health research networks.
- Exploring the application of new methods such as clinical trials or database research, as well as other appropriate research methods, to understand the safety of medicines.
- Conducting methodological research in pharmacovigilance and pharmacoepidemiology.
- Conducting studies and other scientific activities such as organising meetings and conferences to explore and develop new methods and innovations in pharmacovigilance and pharmacoepidemiology.
- Undertaking reviews, systematic reviews, meta-analyses or benefit-risk studies to answer drug safety and drug utilisation questions.
- Establishing research entities for studying and communicating methodological issues in pharmacovigilance and drug safety issues
- Leading or participating in national and international research networks and scientific collaborative projects.

We continue to monitor developments in the UK relationship with the EU and make adjustments to our systems as appropriate to address relevant issues arising from these changes. In this regard the Trust has already opened a sub-office in Dublin to maintain and develop our links with the EU following the UK's severance of membership of the EU in 2020. The Director keeps in regular contact with the Regulatory Agencies and our European colleagues to obtain information in order to shape our strategy and policy, particularly on matters related to the impact of Brexit on medicines regulations and medical research.

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

#### **OBJECTIVES AND ACTIVITIES**

##### **Significant activities**

The DSRU provides advice, education and training in pharmacovigilance and related subjects and works to improve the methods used to study and understand the safety of medicines. As one of the main providers of training and education in pharmacovigilance in Europe, its activities include:

- Providing a range of training courses in pharmacovigilance and pharmacoepidemiology. The DSRU currently provides 18 courses per year, including academically endorsed higher education in collaboration with University of Portsmouth for Postgraduate Certificate, Diploma and a Master's degree in Pharmacovigilance and with the Faculty of Pharmaceutical Medicine for providing Pharmaceutical Medicine Specialty Training (PMST) for doctors specialising in pharmaceutical medicine.
- Providing external training and education when required.
- Keeping up with technological progress the DSRU intends to periodically evaluate options such as providing distance learning and other internet based educational methods.
- Arranging national and international conferences in pharmacovigilance and pharmacoepidemiology.
- Providing postgraduate teaching and research opportunities at all levels including MSc and PhD students.
- Supporting postgraduate students who wish to undertake research at the DSRU.
- Providing training in pharmacovigilance and pharmacoepidemiology for pharmaceutical physicians. The DSRU has been selected by the Faculty of Pharmaceutical Medicine to provide Pharmaceutical Medicine Specialty Training (PMST) training in pharmacovigilance in the UK.
- Supporting training and scientific communications on the safety of medicines in the UK and internationally.
- Providing advice on matters related to the safety of medicines.
- Producing newsletters and internet communications to general practitioners on matters to do with drug safety.
- Providing information on drug safety which can be accessed by everyone on the DSRU website.

Routinely, reports on the results of studies are sent to the Medicines and Healthcare Products Regulatory Authority (MHRA) (an executive agency of the Department of Health) and to the European Medicines Agency (EMA) and other Regulatory Authorities in Europe to assist them in their regulatory and monitoring activities of medicines. The DSRU sends reports of its studies to Marketing Authorisation Holders of medicines and vaccines and also publishes findings of its work in scientific journals and at national and international conferences, newsletters and on its website.

Progress of the scientific work of the Unit was satisfactory throughout 2022 extending the breadth of activity to include research projects and collaborations other than Modified Prescription-Event Monitoring (MPeM). These include specialist and hospital-based studies (SCeMs), systematic reviews, registries, structured benefit-risk evaluation, drug utilisation projects and methodological research. In addition, our programme of activities has extended to include collaborating with a broad range of doctors in England through Health Research Networks from differing specialities as well as collaborating with colleagues in Europe. The policy to extend the range of scientific activities, as funding allows, will continue.

Applications for funding from grant-giving bodies, including the Department of Health Targeted Research Programme and other bodies such as the Medical Research Council (MRC), the Wellcome Trust, pharmaceutical companies and European initiatives, e.g., the European Commission, will continue as and when calls are advertised. The DSRU continues to function as one of the leading Units in the field of monitoring and studying the safety of medicines both in the UK and internationally, as well as being a leading organisation in teaching and training in these fields.

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

#### **OBJECTIVES AND ACTIVITIES**

The DSRU has a long-standing partnership with the NHS Rx Services to receive prescription data that are necessary to conduct Modified Prescription-Event Monitoring studies to improve the understanding of the safety of new drugs used in the general population. This partnership has the support of the Department of Health and senior staff at NHS Rx Services.

Since application for Section 251 exemption of the NHS 2006 Act became a requirement, the Trust has applied annually to the Confidentiality Advisory Group (CAG) of the Health Research Authority for approval to use patient data without consent. Application was again made in 2022 and was successful.

The formal collaborative partnership programme agreement, required to develop the partnership with the NHS Rx Services, to supply improved prescription data is in place and we continue to maintain good communications. In the unlikely situation that the DSRU ceases to receive data for whatever reason from the NHS Rx Services, the DSRU is committed to continue its work on studying the safety of medicines by other methods and providing education and training in pharmacovigilance and drug safety.

The main objectives of the Unit for the next year are:

- To continue the monitoring and research programme on the safety and risk management of vaccines and medicinal products for the treatment COVID-19.
- To undertake all forms of studies and evaluations of the safety and benefit-risk of medicines and vaccines alone or in collaboration with other organisations.
- To plan and support organisations to implement risk minimisation measures for medicines and vaccines and monitor the effectiveness of these measures.
- To use its studies to support risk management, risk minimisation and monitoring the effectiveness of risk minimisation and utilisation of medicines and vaccines.
- To conduct studies to understand drug safety issues, undertake methodological research, and explore and conduct studies on new methodologies and innovations.
- To conduct studies to understand the utilisation (use) and effects of medicines and vaccines.
- To continue its scientific work in methodological aspects of drug safety including leading or participating in national and international collaborative projects.
- To continue its activities in advice, education and training in pharmacovigilance and pharmacoepidemiology.
- To consolidate its scientific communications programme such as the DSRU blogs to inform both the medical/scientific communities and the public about important pharmacovigilance issues.
- To continue to try to secure sufficient funding from different sources (public and private) to enable the continuation and growth of the charity's activities.

**Drug Safety Research Trust**

**Trustees' Report  
for the Year Ended 31 December 2022**

**OBJECTIVES AND ACTIVITIES**

**Public benefit**

The Trustees confirm that the Charity Commission's general guidance on public benefit has been considered in relation to the objectives of the Charity.

The objectives, activities, performance and achievement sections of this report clearly set out the activities which the charity undertakes for public benefit. The Trustees confirm that they have complied with their duty in Section 4 of the Charities Act 2006 to have due regard to public benefits guidance published by the Charities Commission in determining the activities undertaken by the Charity.

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

#### **ACHIEVEMENT AND PERFORMANCE**

##### **Charitable activities**

The successful annual submission and subsequent approval and support of the Ethics and Confidentiality Committee of the Confidentiality Advisory Group (CAG) of the Health Research Authority for Section 251 exemption under the NHS Act 2006 was achieved for the thirteenth year running.

The academically endorsed higher educational training in collaboration with the University of Portsmouth for Certificate, Diploma and Masters degree in Pharmacovigilance continued, with 18 students currently enrolled at the end of the year.

Eight scientific papers were published in medical literature. Two poster presentations on the results of studies were given by the Director and research staff at national and international medical and scientific conferences. One Vaccine Active Safety Surveillance study, one Systematic Review and six Interim Reports were completed and delivered during 2022 as well as the provision of pharmacovigilance consultancy support to pharmaceutical companies.

##### **Education and Professional Capability**

The educational training of staff has been maintained, including continuing professional development. In addition, the DSRU has provided advice on safety of medicines issues.

##### **Teaching & Education**

The Director taught at an MSc Course at Oxford University. In addition, teaching and presenting at national and international scientific meetings continued by both the Director and senior scientific staff enabling the scientific profile of the Unit and its work in public health and drug safety to be maintained.

The DSRU and staff at the DSRU have provided training for general practitioners on effective and safe prescribing of medicines.

##### **Training Courses for Pharmaceutical Medicine Speciality Training**

The DSRU continues to deliver teaching courses in pharmacovigilance, providing training on drug safety modules of Pharmaceutical Medicine Specialty Training (PMST), for pharmaceutical physicians on behalf of the Faculty of Pharmaceutical Medicine, Royal College of Physicians. Eight students attended these modules during the year.

##### **Partners and Stakeholders**

Universities of Portsmouth

Collaborations with the University of Portsmouth on joint studentships and joint training continue.

##### **Regulatory Agencies**

Close links were maintained throughout the year with the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) with regular reports on safety issues submitted, contributing to the better understanding of the safety of a number of important medicinal products. The DSRU is a member of the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP), a project led by the European Medicines Agency and developed in collaboration with European experts in the fields of pharmacoepidemiology and pharmacovigilance. Senior staff of the DSRU regularly participate in meetings of the ENCePP network group.

##### **VAC4EU**

The DSRU is a member of VAC4EU which is a collaborative network of 46 units across Europe which conduct studies on the safety and effectiveness of vaccines. The network is led by Professor Miriam Sturkenboom (the University of Utrecht in the Netherlands). The DSRU is conducting three studies on COVID-19 vaccines in collaboration with members of VAC4EU. The DSRU is using Clinical Practice Research Datalink (CPRD), the leading resource in the UK of primary care clinical data to conduct the studies on COVID-19 vaccines by AstraZeneca, Pfizer and Moderna, while our collaborators are using databases in a number of European countries.

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

#### **Lareb**

The DSRU is running the UK arm of the Covid Vaccine Monitor Study, a European-wide study organised by the Netherlands Pharmacovigilance Centre, Lareb. In this study a web app is used to monitor the safety of all COVID-19 vaccines amongst vaccinees in seven European countries. The aims of the study are to generate incidence rates of patient-reported ADRs for each COVID-19 vaccine brand in near real time and to describe differences in those incidence rates between different vaccine batches used across the participating countries. EU work package partners are using anonymised, aggregated data from all countries to produce a dashboard for the monitoring of side effects and signal detection.

#### **International scientific leadership collaboration**

The DSRU is leading an International Working Group (IWG) for New Developments in Pharmacovigilance. The Group includes some of the best experts in the world in this field. The objective is to examine the impact of new developments in biomedical sciences on signal detection and management in pharmacovigilance. Such developments include artificial intelligence and machine thinking, the use of big data, the application of genetic knowledge in detecting and evaluating adverse drug reactions. The work of the IWG was interrupted for nearly two years because of the COVID-19 pandemic but the group re-started in October 2022 and has made good progress in its activities with broader objectives which are to address new developments in pharmacovigilance and pharmacoepidemiology.

#### **Investment performance**

##### **Special investment powers of the Trustees**

The Trust has undertaken investment in equities and bonds through Investec Wealth & Investment Ltd. In order to monitor the investment portfolio performance, two Trustees and the Director act as a sub-committee. This group, on behalf of the Board of Trustees, deals with all matters relating to the investment portfolio and meets with representatives of Investec Wealth & Investment Ltd at appropriate intervals. It is the policy of the Board of Trustees that no investments in the pharmaceutical, armaments or tobacco industries should be undertaken. The Trustees are satisfied that the current investment approach of the Trust is consistent with its investment needs, objectives and attitude to risk, which is to provide a balanced return on investment in the medium term with a moderate risk of capital loss.

## **FINANCIAL REVIEW**

### **Financial position**

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the charity's Trust Deed, the Charities Act 1993 and the Statement of Recommended Practice, "Accounting and Reporting by Charities", issued in March 2005.

The Statement of Financial Activities for the year is set out on page 14 to these financial statements.

### **Principal funding sources**

Principle funding sources come from donations received from pharmaceutical companies and other organisations in order to carry out charitable activities.

Whilst some costs are provided in advance by funders, the entitlement to income only arises when separately identifiable stages of the projects are completed. The charity monitors the progress of the projects closely and only includes the income and associated costs as and when these conditions are met. This treatment meets the charity's accounting policy regarding incoming resources as set out under accounting policy 1.2 in the notes to the financial statements..

Staffing costs were higher in 2022 at £1,485,552 compared to £1,361,121 in 2021. Salaries still form the major part of the charity's expenses due to the specialist nature of employees, e.g., medical doctors and scientists needed to carry out the research activities. Total wage costs including national insurance and pension contributions therefore remain the highest expenditure for the Trust on a year-by-year basis.

The Chairman of Trustees and Director maintained close scrutiny of incoming resources and expenditure during the year and kept the Board informed maintaining the same level of financial governance as in previous years.

## **Drug Safety Research Trust**

### **Trustees' Report for the Year Ended 31 December 2022**

#### **FINANCIAL REVIEW**

##### **Investment policy and objectives**

The Trust has undertaken investment in equities and bonds through Investec Wealth & Investment Ltd. In order to monitor the investment portfolio performance, two Trustees and the Director act as a sub-committee. This group, on behalf of the Board of Trustees, deals with all matters relating to the investment portfolio and meets with representatives of Investec Wealth & Investment Ltd at appropriate intervals. It is the policy of the Board of Trustees that no investments in the pharmaceutical, armaments or tobacco industries should be undertaken. The Trustees were satisfied that the current investment approach of the Trust is consistent with its investment needs, objectives and attitude to risk, which is to provide a balanced return on investment in the medium term with a moderate risk of capital loss.

Annually from a management perspective all other funds not immediately required from month to month for the normal running of the DSRU are routinely invested in fixed term deposit accounts to maximise return whenever possible.

The Trust's strategy to invest whenever possible to offset for leaner years when donations are reduced, will be maintained. The return on investment increased from £49,452 in 2021 to £63,666 in 2022.

##### **Reserves policy**

It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity. This provides sufficient funds to cover the cost of ongoing studies, management and administration costs. Considering expected fluctuations of future income, the financial reserves are necessary to maintain the future stability and viability of the DSRU. These reserves will be used when and if funds become too low to cover normal day to day activities. In these difficult economic times, the Trust is reaping the benefit of the prudent financial policy in the last decade. This approach will be continued in line with developments in the external economic environment.

##### **Asset cover for funds**

An analysis of the assets attributable to the various funds described is set out in the notes to these financial statements. These assets are sufficient to meet the charity's obligations on a fund by fund basis.

#### **FUTURE PLANS**

The overall strategy remains the same. As in previous years the DSRU will endeavour to ensure the preservation of Modified Prescription-Event Monitoring (MPeM) as a leading system to monitor the safety of medicines in the UK and to enhance and develop it. The Unit will continue to conduct a broad range of studies to address safety questions, including add-on studies, such as case-control and case-series studies within our databases, pharmacoepidemiological studies using other data sources and a range of study designs, appropriate clinical trials, genetic studies, drug and vaccine utilisation studies, meta-analyses, systematic reviews, benefit-risk evaluation, other study methods to understand drugs and vaccines safety, effectiveness use and utilisation.

The DSRU will conduct methodological research to contribute to advance the science and methods of Pharmacovigilance. These are part of the DSRU's objective to explore conducting studies with different methods, including using a range of data sources and innovations that enable it to achieve its objective to monitor and study the safety of medicines.

The DSRU will continue its recent successful expansion to conduct safety studies in secondary care as well as in primary care using appropriate and improved methods to answer the relevant safety questions.

The DSRU will lead or participate in national and international collaborative projects that aim to improve the methods and advance the science of studying the safety of medicines. The DSRU will further develop its scientific communications programme to inform the both the medical/scientific communities and the public about important pharmacovigilance issues.

The DSRU continues to monitor IT and other developments in the NHS and elsewhere to ensure that it benefits from the opportunities provided by these developments. The Unit will further develop its methods and capabilities in evidence-based pharmacovigilance and risk management and maintain its place as a leading Unit in providing advice, training and education in pharmacovigilance and drug safety. The DSRU will try to review and improve where necessary its systems such as its IT database.

## Drug Safety Research Trust

### Trustees' Report for the Year Ended 31 December 2022

#### STRUCTURE, GOVERNANCE AND MANAGEMENT

##### Governing document

The Trust is governed by a charitable Trust Deed established on 23 July 1986 with a Board of Trustees five in number. The Mission of the Trust remains to monitor, study and communicate the safety of medicines independent from both Government and industry. The Trust by way of its operational unit, the Drug Safety Research Unit (DSRU), undertakes all forms of studies and evaluations on the safety of medicines. The DSRU provides advice, training and education in pharmacovigilance and related subjects and works to improve the methods used to study and understand the safety of medicines.

As an independent registered medical charity, its aim is to achieve the highest possible scientific and ethical standards by putting the interests of patients first and to work with integrity and fairness with all partners.

##### Recruitment and appointment of new trustees

As a charity specialising in drug safety, the Trustees are identified for their expertise in areas which include drug regulation, epidemiology and medical statistics, experimental medicine and pharmacovigilance. Once appointed, the Trust ensures that any training required by the Trustees is provided to enable them to fulfil their role.

##### Organisational structure

The Trust employs a Director, Professor Saad Shakir, assisted by scientific, professional and administrative staff to conduct its day-to-day activities, ensuring that the charity's objectives are implemented. The Trust also retains the services of appropriate advisers and consultants depending upon the nature of the tasks required. During 2022 the average number of staff employed for the year was 33. In addition, fourteen consultants were engaged, to advise and assist with additional medical/research input, IT and data protection and PR.

##### Induction and training of new trustees

The Trustees acknowledge their responsibilities as set out on the statement of "Trustees responsibilities".

##### Changes to the Board of Trustees

There have been no changes during 2022.

##### Risk management

The Trustees have a duty to identify and review the risks to which the Charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

The Trustees examine the major strategic, business and operational risks and confirm that systems are established to enable regular reports to be produced, so that necessary steps can be taken to control or lessen these risks. The variability of the funding of the Trust made it necessary to put in place processes to ensure that staff felt secure and motivated.

A Disaster Recovery Plan for the DSRU has been designed and completed. The plan is secured in off-site storage within a data safe.

Approved by order of the board of trustees on 30 MAY 2023 and signed on its behalf by:



.....  
Professor K R Paterson MB ChB FRCP FFPM - Trustee

## **Drug Safety Research Trust**

### **Statement of Trustees' Responsibilities for the Year Ended 31 December 2022**

The trustees are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and Financial Reporting Standards (FRS102).

The law applicable to charities in England and Wales requires the trustees to prepare Accounts for each financial year which give a true and fair view of the charity's financial activities during the year and of its financial position at the end of the year (unless the charity is entitled to prepare accounts on the alternative receipts and payments basis).

In preparing accounts giving a true and fair view, the trustees should follow best practice and:

- Select suitable accounting policies and then apply them consistently;
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any departures and explained in the accounts.
- make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the applicable law. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **Report of the Independent Auditors to the Trustees of Drug Safety Research Trust**

### **Opinion**

We have audited the financial statements of Drug Safety Research Trust (the 'charity') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2022 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

### **Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the trustees Report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

**Report of the Independent Auditors to the Trustees of  
Drug Safety Research Trust**

**Responsibilities of trustees**

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

## **Report of the Independent Auditors to the Trustees of Drug Safety Research Trust**

### **Our responsibilities for the audit of the financial statements**

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

We ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations, and that they remained alert to instances of non-compliance throughout the audit.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- based on our understanding of the charity and sector, and through discussions with trustees and key management, we identified any specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charity, including the SORP 2015, Companies Act 2006, taxation legislation and data protection, anti-bribery, employment, environmental and health and safety legislation; and
- we assessed the extent of compliance with these laws and regulations through making enquiries of management and inspecting legal correspondence.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries, particularly focused around the year-end, to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates in the notes to the financial statements were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC, relevant regulators and the charity's legal advisors.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Report of the Independent Auditors to the Trustees of  
Drug Safety Research Trust**

**Use of our report**

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Cartwrights  
Chartered Accountants and Business Advisors  
Statutory Auditor  
Regency House  
33 Wood Street  
Barnet  
Hertfordshire  
EN5 4BE

Date: ..... 01/06/2023

Andrew Hill FCA (Senior Statutory Auditor) for and on behalf of Cartwrights

**Drug Safety Research Trust**

**Statement of Financial Activities  
for the Year Ended 31 December 2022**

	Notes	Unrestricted funds £	Restricted fund £	31/12/22 Total funds £	31/12/21 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	2	1,063,010	-	1,063,010	3,375,220
Investment income	3	132,385	-	132,385	149,016
Other income		713,303	-	713,303	506,826
<b>Total</b>		<u>1,908,698</u>	<u>-</u>	<u>1,908,698</u>	<u>4,031,062</u>
<b>EXPENDITURE ON</b>					
Raising funds	4	23,364	-	23,364	21,974
<b>Charitable activities</b>					
Direct Charitable Expenditure	5	1,994,174	18,780	2,012,954	2,157,209
Other		647,027	-	647,027	615,604
<b>Total</b>		<u>2,664,565</u>	<u>18,780</u>	<u>2,683,345</u>	<u>2,794,787</u>
Net gains/(losses) on investments		<u>(494,633)</u>	<u>-</u>	<u>(494,633)</u>	<u>230,072</u>
<b>NET INCOME/(EXPENDITURE)</b>		<u>(1,250,500)</u>	<u>(18,780)</u>	<u>(1,269,280)</u>	<u>1,466,347</u>
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		9,564,348	471,840	10,036,188	8,569,841
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><u>8,313,848</u></u>	<u><u>453,060</u></u>	<u><u>8,766,908</u></u>	<u><u>10,036,188</u></u>

The notes form part of these financial statements

**Drug Safety Research Trust**

**Statement of Financial Position  
31 December 2022**

	Notes	Unrestricted funds £	Restricted fund £	31/12/22 Total funds £	31/12/21 Total funds £
<b>FIXED ASSETS</b>					
Tangible assets	9	19,980	453,060	473,040	493,950
Investments	10	3,831,919	-	3,831,919	4,224,909
		<u>3,851,899</u>	<u>453,060</u>	<u>4,304,959</u>	<u>4,718,859</u>
<b>CURRENT ASSETS</b>					
Debtors	11	235,427	-	235,427	344,120
Cash at bank		4,348,571	-	4,348,571	5,104,031
		<u>4,583,998</u>	<u>-</u>	<u>4,583,998</u>	<u>5,448,151</u>
<b>CREDITORS</b>					
Amounts falling due within one year	12	(122,049)	-	(122,049)	(130,822)
<b>NET CURRENT ASSETS</b>					
		<u>4,461,949</u>	<u>-</u>	<u>4,461,949</u>	<u>5,317,329</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
		<u>8,313,848</u>	<u>453,060</u>	<u>8,766,908</u>	<u>10,036,188</u>
<b>NET ASSETS</b>					
		<u>8,313,848</u>	<u>453,060</u>	<u>8,766,908</u>	<u>10,036,188</u>
<b>FUNDS</b>					
	13				
Unrestricted funds				8,313,848	9,564,348
Restricted funds				453,060	471,840
<b>TOTAL FUNDS</b>					
				<u>8,766,908</u>	<u>10,036,188</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 30 MAY 2023 and were signed on its behalf by:



.....  
K R Paterson MB ChB FRCP FFPM - Trustee

The notes form part of these financial statements

**Drug Safety Research Trust**

**Statement of Cash Flows  
for the Year Ended 31 December 2022**

	Notes	31/12/22 £	31/12/21 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	(240,785)	703,704
Net cash (used in)/provided by operating activities		<u>(240,785)</u>	<u>703,704</u>
<b>Cash flows from investing activities</b>			
Purchase of tangible fixed assets		(9,429)	(8,614)
Purchase of fixed asset investments		(101,643)	(575,793)
Sale of fixed asset investments		(494,633)	230,072
Interest received		27,364	13,304
Dividends received		63,666	49,452
Net cash used in investing activities		<u>(514,675)</u>	<u>(291,579)</u>
<b>Change in cash and cash equivalents in the reporting period</b>		<u>(755,460)</u>	<u>412,125</u>
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>5,104,031</u>	<u>4,691,906</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>4,348,571</u></u>	<u><u>5,104,031</u></u>

The notes form part of these financial statements

**Drug Safety Research Trust**

**Notes to the Statement of Cash Flows  
for the Year Ended 31 December 2022**

**1. RECONCILIATION OF NET (EXPENDITURE)/INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	31/12/22	31/12/21
	£	£
<b>Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)</b>	(1,269,280)	1,466,347
<b>Adjustments for:</b>		
Depreciation charges	30,339	33,547
Losses/(gain) on investments	989,266	(460,144)
Interest received	(27,364)	(13,304)
Dividends received	(63,666)	(49,452)
Decrease/(increase) in debtors	108,693	(332,629)
(Decrease)/increase in creditors	(8,773)	59,339
	<u>(240,785)</u>	<u>703,704</u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1/1/22	Cash flow	At 31/12/22
	£	£	£
<b>Net cash</b>			
Cash at bank	5,104,031	(755,460)	4,348,571
	<u>5,104,031</u>	<u>(755,460)</u>	<u>4,348,571</u>
<b>Total</b>	<u>5,104,031</u>	<u>(755,460)</u>	<u>4,348,571</u>

The notes form part of these financial statements

## **Drug Safety Research Trust**

### **Notes to the Financial Statements for the Year Ended 31 December 2022**

#### **1. ACCOUNTING POLICIES**

##### **Basis of preparing the financial statements**

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

##### **Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

For donations to be recognised the charity will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity and it is probable that they will be fulfilled.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends, interest and unrealised gains or losses on shares held. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Interest income is recognised using the effective interest method and dividend income is recognised as the charity's right to receive payment is established.

Other income represents management fees charged and donations received from the Trust's connected trading entity, DSRU Education and Research Limited. Management fees are included when charged and donations when received. Due to the connected nature of this entity, donation income is recorded within other income rather than within donations and legacy income in the Statement of Financial Activities.

##### **Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

##### **Raising funds**

Costs of raising funds represent investment manager costs incurred in dealing with the listed investment portfolio

##### **Charitable activities**

Expenditure on charitable activities includes the direct costs of carrying out and performing the studies and evaluations of medicines in order to meet the Trust's objectives and aims.

##### **Allocation and apportionment of costs**

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office costs, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. Premises overheads have been allocated on an insert detail basis and other overheads have been allocated on an insert detail basis..

## Drug Safety Research Trust

### Notes to the Financial Statements - continued for the Year Ended 31 December 2022

#### 1. ACCOUNTING POLICIES - continued

##### **Tangible fixed assets**

Tangible fixed assets other than freehold land are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Freehold land	Not depreciated
Freehold buildings	2% Straight line on cost
Plant and machinery	20% straight line on cost
Fixtures, fittings and equipment	20% Straight line on cost
Motor vehicles	20% Straight line on cost

##### **Taxation**

The charity is exempt from tax on its charitable activities.

##### **Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

##### **Pension costs and other post-retirement benefits**

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

##### **Accumulated funds**

The restricted fund represents the net book values of the freehold land and buildings at Bursledon Hall, Southampton. The fund balances are reduced by the depreciation charged on the buildings.

##### **Unrestricted Funds**

Unrestricted funds represent donations and other incoming resources receivable or generated for the objects of the charity without further specified purpose and are available as general funds.

##### **Investments**

Fixed asset investments are stated at market value.

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**2. DONATIONS AND LEGACIES**

	<b>Unrestricted funds £</b>	<b>Restricted funds £</b>	<b>31/12/22 Total funds £</b>	<b>31/12/21 Total funds £</b>
Donations	1,063,010	-	1,063,010	3,375,220

**3. INVESTMENT INCOME**

	<b>Unrestricted funds £</b>	<b>Restricted funds £</b>	<b>31/12/22 Total funds £</b>	<b>31/12/21 Total funds £</b>
Gain on disposal of investment	41,355	-	41,355	86,260
Listed income	63,666	-	63,666	49,452
Interest received	27,364	-	27,364	13,304
	<u>132,385</u>	<u>-</u>	<u>132,385</u>	<u>149,016</u>

**4. RAISING FUNDS**

**Investment management costs**

	<b>Unrestricted funds £</b>	<b>Restricted funds £</b>	<b>31/12/22 Total funds £</b>	<b>31/12/21 Total funds £</b>
Fund manager costs	23,364	-	23,364	21,974

**5. CHARITABLE ACTIVITIES COSTS**

	<b>Direct Costs £</b>
Direct Charitable Expenditure	<u>2,012,954</u>

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**6. SUPPORT COSTS**

	<b>Governance costs £</b>
Other resources expended	<u>647,027</u>

Support costs, included in the above, are as follows:

	<b>31/12/22 Other resources expended £</b>	<b>31/12/21 Total activities £</b>
Wages	169,322	167,080
Social security	154,469	134,680
Pensions	65,396	62,210
Auditors' remuneration	10,773	11,368
Rates and water	10,559	10,598
Insurance	19,718	17,634
Light and heat	22,597	16,242
Telephone and fax	8,627	17,409
PPS	3,740	11,251
Sundries	3,284	2,880
Repairs and maintenance	12,718	12,085
Staff training	-	8,660
Staff medical costs	11,080	10,140
Motor and travel expenses	18,690	5,837
Computer costs	15,567	12,715
Subscriptions	49,861	30,260
Bank charges	1,376	1,365
Marketing costs	35,690	47,063
Equipment hire	3,221	2,580
Depreciation of tangible fixed assets	30,339	33,547
	<u>647,027</u>	<u>615,604</u>

**7. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**7. TRUSTEES' REMUNERATION AND BENEFITS - continued**

**Trustees' expenses**

Travelling expenses amounting to £0 (2021 - £0) were reimbursed to the trustees for attending meetings.

Trustees indemnity insurance payable during the year amounted to £6,660 (2021: £6,858).

**8. STAFF COSTS**

The average number of employees during the year was 33 (2021 - 30).

The number of employees whose annual emoluments were £60,000 or more were:

	2022	2021
£230,001 - £300,000	1	-
£220,001 - £230,000	-	1
£60,001 - £70,000	5	1

**9. TANGIBLE FIXED ASSETS**

	Freehold property £	Plant and machinery £	Fixtures and fittings £	Computer system £	Totals £
<b>COST</b>					
At 1 January 2022	941,000	168,940	66,368	57,036	1,233,344
Additions	-	9,429	-	-	9,429
At 31 December 2022	<u>941,000</u>	<u>178,369</u>	<u>66,368</u>	<u>57,036</u>	<u>1,242,773</u>
<b>DEPRECIATION</b>					
At 1 January 2022	469,160	153,403	59,795	57,036	739,394
Charge for year	18,780	9,036	2,523	-	30,339
At 31 December 2022	<u>487,940</u>	<u>162,439</u>	<u>62,318</u>	<u>57,036</u>	<u>769,733</u>
<b>NET BOOK VALUE</b>					
At 31 December 2022	<u>453,060</u>	<u>15,930</u>	<u>4,050</u>	<u>-</u>	<u>473,040</u>
At 31 December 2021	<u>471,840</u>	<u>15,537</u>	<u>6,573</u>	<u>-</u>	<u>493,950</u>

The freehold property was last revalued on 20 December 1999 by Messrs Daniells Harison, Chartered Surveyors, on the basis of open market value for current use. The freehold land and buildings valuation has not been updated since 1999. Under the transitional relief provisions under FRS 102, this value has been treated as the deemed cost in these financial statements. The estimated market value as at the balance sheet date is in excess of £4 million.

Comparable historical cost for the land and buildings included at valuation:

	2022 £	2021 £
Cost	1,487,614	1,487,614
Accumulated Depreciation	487,940	469,160
At year end	<u>999,674</u>	<u>1,018,454</u>

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**9. TANGIBLE FIXED ASSETS - continued**

All other tangible fixed assets are stated at historical cost.

**10. FIXED ASSET INVESTMENTS**

	<b>Listed investments £</b>
<b>MARKET VALUE</b>	
At 1 January 2022	4,224,909
Additions	101,643
Revaluations	(494,633)
	<hr/>
At 31 December 2022	3,831,919
	<hr/>
<b>NET BOOK VALUE</b>	
At 31 December 2022	3,831,919
	<hr/>
At 31 December 2021	4,224,909
	<hr/>

There were no investment assets outside the UK.

Cost or valuation at 31 December 2022 is represented by:

	<b>Listed investments £</b>
Valuation in 2022	3,831,919
	<hr/>

Net additions at cost represent investment income reinvested at source in the relevant funds held.

**11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>31/12/22 £</b>	<b>31/12/21 £</b>
Trade debtors	202,409	312,686
Prepayments and accrued income	33,018	31,434
	<hr/>	<hr/>
	235,427	344,120
	<hr/>	<hr/>

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31/12/22	31/12/21
	£	£
Trade creditors	27,647	23,881
Taxation and social security	48,103	75,968
Other creditors	46,299	30,973
	<u>122,049</u>	<u>130,822</u>

**13. MOVEMENT IN FUNDS**

	At 1/1/22	Net movement in funds	At 31/12/22
	£	£	£
<b>Unrestricted funds</b>			
Unrestricted Fund	9,564,348	(1,250,500)	8,313,848
<b>Restricted funds</b>			
Restricted Fund	471,840	(18,780)	453,060
<b>TOTAL FUNDS</b>	<u>10,036,188</u>	<u>(1,269,280)</u>	<u>8,766,908</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
<b>Unrestricted funds</b>				
Unrestricted Fund	1,908,698	(2,664,565)	(494,633)	(1,250,500)
<b>Restricted funds</b>				
Restricted Fund	-	(18,780)	-	(18,780)
<b>TOTAL FUNDS</b>	<u>1,908,698</u>	<u>(2,683,345)</u>	<u>(494,633)</u>	<u>(1,269,280)</u>

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**13. MOVEMENT IN FUNDS - continued**

**Comparatives for movement in funds**

	At 1/1/21 £	Net movement in funds £	At 31/12/21 £
<b>Unrestricted funds</b>			
Unrestricted Fund	8,079,221	1,485,127	9,564,348
<b>Restricted funds</b>			
Restricted Fund	490,620	(18,780)	471,840
<b>TOTAL FUNDS</b>	<u>8,569,841</u>	<u>1,466,347</u>	<u>10,036,188</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
<b>Unrestricted funds</b>				
Unrestricted Fund	4,031,062	(2,776,007)	230,072	1,485,127
<b>Restricted funds</b>				
Restricted Fund	-	(18,780)	-	(18,780)
<b>TOTAL FUNDS</b>	<u>4,031,062</u>	<u>(2,794,787)</u>	<u>230,072</u>	<u>1,466,347</u>

**14. EMPLOYEE BENEFIT OBLIGATIONS**

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund. These amounted to £65,396 (2021 - £62,210). Contributions totalling £9,351 (2021 - £25,119) were payable to the fund at the year end and are included in creditors.

**Drug Safety Research Trust**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2022**

**15. RELATED PARTY DISCLOSURES**

Other income includes the following income received from DSRU Education and Research Trust, a company limited by guarantee, which is controlled by the Charity and in which Professor Saad Shakir is sole company director. During the year:

Management fees totalling £78,000 (2021: £78,000) were charged to the company for use of shared premises and administrative resources;

Salary recharges totalling £35,353 (2021: 33,276) were made to the company for the use of shared staff; and

A donation of £599,950 (2021: £395,550) was received from the company. The value of the donation each year is determined such that the company reduces its profits chargeable to tax to £nil each year.

**Drug Safety Research Trust****Detailed Statement of Financial Activities  
for the Year Ended 31 December 2022**

	31/12/22	31/12/21
	£	£
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	1,063,010	3,375,220
<b>Investment income</b>		
Gain on disposal of investment	41,355	86,260
Listed income	63,666	49,452
Interest received	27,364	13,304
	<hr/>	<hr/>
	132,385	149,016
<b>Other income</b>		
Other income	713,303	506,826
	<hr/>	<hr/>
<b>Total incoming resources</b>	1,908,698	4,031,062
<b>EXPENDITURE</b>		
<b>Investment management costs</b>		
Fund manager costs	23,364	21,974
<b>Charitable activities</b>		
Wages - direct	1,161,761	1,059,361
General Practitioner costs	51,932	149,555
Other direct costs	799,261	948,293
	<hr/>	<hr/>
	2,012,954	2,157,209
<b>Support costs</b>		
<b>Governance costs</b>		
Wages	169,322	167,080
Social security	154,469	134,680
Pensions	65,396	62,210
Auditors' remuneration	10,773	11,368
Rates and water	10,559	10,598
Insurance	19,718	17,634
Light and heat	22,597	16,242
Telephone and fax	8,627	17,409
PPS	3,740	11,251
Sundries	3,284	2,880
Repairs and maintenance	12,718	12,085
Staff training	-	8,660
Carried forward	481,203	472,097

This page does not form part of the statutory financial statements

**Drug Safety Research Trust**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2022**

	<b>31/12/22</b>	<b>31/12/21</b>
	<b>£</b>	<b>£</b>
<b>Governance costs</b>		
Brought forward	481,203	472,097
Staff medical costs	11,080	10,140
Motor and travel expenses	18,690	5,837
Computer costs	15,567	12,715
Subscriptions	49,861	30,260
Bank charges	1,376	1,365
Marketing costs	35,690	47,063
Equipment hire	3,221	2,580
Depreciation of tangible fixed assets	30,339	33,547
	<u>647,027</u>	<u>615,604</u>
Total resources expended	<u>2,683,345</u>	<u>2,794,787</u>
<b>Net (expenditure)/income before gains and losses</b>	(774,647)	1,236,275
<b>Net losses on investments</b>		
Net gains / losses on investments	<u>(494,633)</u>	<u>230,072</u>
<b>Net (expenditure)/income</b>	<u><u>(1,269,280)</u></u>	<u><u>1,466,347</u></u>

This page does not form part of the statutory financial statements

